The Three Receptor Tyrosine Kinases c-KIT, VEGFR2 and PDGFRα, Closely Spaced at 4q12, Show Increased Protein Expression in Triple-Negative Breast Cancer

Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up

(2013) Anna-Karin Falck et al.   BREAST CANCER RESEARCH AND TREATMENT

c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer

(2013) S. Kashiwagi et al.   BRITISH JOURNAL OF SURGERY

Protein Kinase C α Is a Central Signaling Node and Therapeutic Target for Breast Cancer Stem Cells

(2013) Wai Leong Tam et al.   CANCER CELL

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles

(2013) Patrycja Gazinska et al.   MODERN PATHOLOGY

Distinct Phenotypic Differences Associated with Differential Amplification of Receptor Tyrosine Kinase Genes at 4q12 in Glioblastoma

(2013) Anna Burford et al.   PLoS One

Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study

(2012) Anna-Karin Falck et al.   BMC CANCER

Inference of the Basal Epithelial Phenotype in Breast Carcinoma from Differential Marker Expression, Using Tissue Microarrays in Triple Negative Breast Cancer and Women Younger than 35

(2012) Aziza Nassar et al.   Breast Journal

Expression of vascular endothelial growth factor and vascular endothelial growth factor receptors 1 and 2 in invasive breast carcinoma: prognostic significance and relationship with markers for aggressiveness

(2012) Hari Prasad Dhakal et al.   HISTOPATHOLOGY

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

(2012) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

(2011) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Twist1-Induced Invadopodia Formation Promotes Tumor Metastasis

(2011) Mark A. Eckert et al.   CANCER CELL

Increased gene copy number of KIT and VEGFR2 at 4q12 in primary breast cancer is related to an aggressive phenotype and impaired prognosis

(2011) Ida Johansson et al.   GENES CHROMOSOMES & CANCER

Targeted therapies for breast cancer

(2011) Michaela J. Higgins et al.   JOURNAL OF CLINICAL INVESTIGATION

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Gene expression profiling in breast cancer: classification, prognostication, and prediction

(2011) Jorge S Reis-Filho et al.   LANCET

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

(2010) Carlos H. Barrios et al.   BREAST CANCER RESEARCH AND TREATMENT

Characteristics of triple-negative breast cancer

(2010) Tim C. de Ruijter et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies

(2010) Daniel J. Toft et al.   MOLECULAR ENDOCRINOLOGY

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib Treatment

(2010) Jan Zietsch et al.   PLoS One

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

(2009) M. Kozloff et al.   ANNALS OF ONCOLOGY

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype

(2008) D. Sarrio et al.   CANCER RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

How basal are triple-negative breast cancers?

(2008) François Bertucci et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

(2008) Harold J. Burstein et al.   JOURNAL OF CLINICAL ONCOLOGY

Cutaneous T-cell lymphoma-associated lung cancers show chromosomal aberrations differing from primary lung cancer

(2007) Sonja Hahtola et al.   GENES CHROMOSOMES & CANCER